Si Zhibo, Fan Yuhang, Wang Mingxuan, Zhao Jing, Zhang Yunmei, Liu Dongmei, Zheng Yajuan
Department of Ophthalmology, The Second Hospital of Jilin University, Jilin University, Changchun 130000, Jilin, China.
Department of Geriatrics, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin 300000, China.
Int J Biol Sci. 2025 Jan 1;21(1):211-232. doi: 10.7150/ijbs.103222. eCollection 2025.
Glaucoma is a neurodegenerative disorder marked by the loss of retinal ganglion cells (RGCs) and axonal degeneration, resulting in irreversible vision impairment. While intraocular pressure (IOP) is presently acknowledged as the sole modifiable risk factor, the sensitivity of RGCs to IOP varies among individuals. Consequently, progressive vision loss may ensue even when IOP is effectively managed. This review consolidates current knowledge regarding the pathogenesis of RGCs in glaucoma and various neurodegenerative diseases. It delves into the mechanisms underlying RGC transsynaptic degeneration and axonal defects in glaucoma from a pathophysiological standpoint, and it elucidates the alterations in the visual pathway throughout the progression of the disease. Furthermore, the article outlines neuroprotective and nerve regeneration strategies aimed at vision restoration in glaucoma patients, offers insights for clinical management of the condition, and investigates prospective avenues for gene therapy.
青光眼是一种神经退行性疾病,其特征是视网膜神经节细胞(RGCs)丧失和轴突退化,导致不可逆转的视力损害。虽然目前眼内压(IOP)被认为是唯一可改变的危险因素,但RGCs对IOP的敏感性因人而异。因此,即使眼内压得到有效控制,仍可能出现进行性视力丧失。本综述整合了目前关于青光眼和各种神经退行性疾病中RGCs发病机制的知识。它从病理生理学角度深入探讨了青光眼RGC跨突触变性和轴突缺陷的潜在机制,并阐明了疾病进展过程中视觉通路的变化。此外,本文概述了旨在恢复青光眼患者视力的神经保护和神经再生策略,为该疾病的临床管理提供了见解,并研究了基因治疗的潜在途径。